Entries by ginealach

Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases

Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced a Series B extension investment by the Dementia Discovery Fund (DDF). The investment is in recognition of the progress made in relation to Amphista’s Eclipsys™ platform and its potential to enable therapies to treat […]

Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022

Cambridge, UK – September 12, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry. Amphista is a world leading next-generation […]

Amphista Therapeutics appoints Dr Stuart Wood as VP, Discovery Technology

Cambridge, UK, 7 July 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Stuart Wood as Vice President of Discovery Technology. Stuart has held a series of leadership roles in Biotech for over ten years, most recently as Chief Technology Officer at Nanna Therapeutics. […]